金沙4399js网站-金沙最新登录入口

Industry News

24 2020-08

2020年08月24日

Recently (July 14), Roche announced that its CD20xCD3 T cell combined with dual-characteristic cancer immunotherapy mosunetuzumab has received FDA Breakthrough Therapy Designation (BTD). Dr. Levi Garraway, Roches Chief Medical Officer and He...
24 2020-08

2020年08月24日

Last week, during the review process of GlaxoSmithKlines targeted BCMA-ADC (antibody-drug conjugate)---Belantamab mafodotin, FDA staff expressed concern about the ocular toxicity and side effects of the drug treatment, although Ge Lan Su Shi...
24 2020-08

2020年08月24日

On July 15, 2020, San Diego BioAtla, Inc. (BioAtla) is a global clinical stage biotechnology company dedicated to the development of conditional activated biological (CAB) antibody therapies. It announced the completion of the D round of fin...
  • Contact information
  • Sales:0512-85557988
  • Personnel Department:0512-85557181
  • Purchasing Department:0512-85557182
  • Links

Follow WeChat public account

Copyright © 2020 Jiangsu Greature Bio-Medicine Co., Ltd All Rights Reserved. 备案号: 苏ICP备20037874号 技术支持:苏州网站建设
share to:
一键拨号 一键导航